The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy
Open accessAbstract
Glucagon-like peptide-1 (GLP-1) receptor agonists are established pharmaceutical therapies for the treatment of type 2 diabetes and obesity. They mimic the action of GLP-1 to reduce glucose levels through stimulation of insulin secretion and inhibition of glucagon secretion. They also reduce body weight by inducing satiety through central actions. The GLP-1 receptor agonists used clinically are based on exendin-4 and native GLP-1 and are available as formulations for daily or weekly s.c. or oral administration. GLP-1 receptor agonism is also achieved by inhibitors of dipeptidyl peptidase-4 (DPP-4), which prevent the inactivation of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), thereby prolonging their raised levels after meal ingestion. Other developments in GLP-1 receptor agonism include the formation of small orally available agonists and compounds with the potential to pharmaceutically stimulate GLP-1 secretion from the gut. In addition, GLP-1/glucagon and GLP-1/GIP dual receptor agonists and GLP-1/GIP/glucagon triple receptor agonists have shown the potential to reduce blood glucose levels and body weight through their effects on islets and peripheral tissues, improving beta cell function and stimulating energy expenditure. This review summarises developments in gut hormone-based therapies and presents the future outlook for their use in type 2 diabetes and obesity. Graphical Abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3 Structures of formulations of GLP-1 receptor agonists [14, 15, 19–21, 26]. (a) GLP-1, (b) exenatide, (c) lixisenatide, (d) efpeglenatide, (e) liraglutide, (f) semaglutide, (g) dulaglutide, (h) albiglutide. Amino acids are illustrated in circles; red circles show amino acids that are different from those in GLP-1. The red arrow in (a) illustrates the site of DPP-4 inactivation. This figure is available as part of a downloadable slideset](https://figures.cochat.ai/paper-figures/ccfebf3c711343c5a6b540b87c7f92a1/gut-hormone-based-pharmacology-novel-formulations-and-future-possibilities-for-figure-3.jpg)
![Fig. 4 Structures of (a) GLP-1, (b) GIP and (c) tirzepatide [19, 88, 90]. Amino acids are illustrated in circles; blue circles show amino acids that are identical to those in GLP-1; black circles show amino acids that are present in GIP and tirzepatide but not in GLP-1; red circles show amino acids that are identical in tirzepatide and exenatide (see Fig. 3b); and green circles show amino acids that are present in tirzepatide but not in GLP-1, GIP or exenatide. AiB, aminoisobutyric acid. This figure is available as part of a downloadable slideset](https://figures.cochat.ai/paper-figures/811627b60550401f876ddf858a6b6b85/gut-hormone-based-pharmacology-novel-formulations-and-future-possibilities-for-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Regarding triple GIPR/GLP-1R/GCGR agonists such as retatrutide, the inclusion of a GCGR moiety may seem counter intuitive given that a key action of GCG is to raise blood glucose by increasing hepatic glucose output [14].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“the dual action on GIP and GLP-1 receptors may confer additive or synergistic effects on glycemic control and appetite regulation, leading to greater weight reductions [59].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 4×
“GLP-1 is a 30 amino acid peptide that is produced by and released from intestinal L cells after meal ingestion and which in turn stimulates insulin secretion [5].”
BackgroundInfluentialSelf-citationSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048 · cited 3×
“Hence, in 2022, glucose-lowering efficacy and proven cardiovascular effects were important for the strong positioning of semaglutide, dulaglutide and tirzepatide in guidelines on the management of hyperglycaemia in type 2 diabetes [33], and a similar strong positioning of incretin therapy was seen in guidelines on pri…”
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“Consistent with this, whole-body GIP receptor deficiency and GIP deficiency protect against obesity induced by long-term high fat feeding in mice [65, 66].”
BackgroundCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 3×
“4 Structures of (a) GLP-1, (b) GIP and (c) tirzepatide [19, 88, 90].”
BackgroundGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837 · cited 1×
“1 3 was isolated from venom produced by the perimandibular glands of the Gila monster (Heloderma suspectum) [18].”
Background
Research works printed but not linked: 1
- Ahrén B (2001) Inhibition of dipeptidyl peptidase-4 (DPP-4): a target to treat type 2 diabetes. Curr Enzyme Inh 7:206–217
Cited by
Enteroendocrine cell regulation of the gut-brain axis
Barton, J. R., Londregan, A., Alexander, T. D., Entezari, A. A., Covarrubias, M., & Waldman, S. A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1272955 · Cited by 101
“Recently, they have come into the spotlight after the recent success of GLP-1 receptor agonists, glucagon analogues, and GIP analogues (Tschöp et al., 2023).”
BackgroundManaging insulin resistance: the forgotten pathophysiological component of type 2 diabetes
Abdul-Ghani, M. A., Maffei, P., & DeFronzo, R. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00127-x · Cited by 89
Gigliotti, L., Warshaw, H., Evert, A., Dawkins, C., Schwartz, J., Susie, C., Kushner, R., Subramanian, S., Handu, D., & Rozga, M. (2025) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2024.10.023 · Cited by 53
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
“Figure 1 schematically depicts the incretin-based agents that are currently used in everyday medical practice or that are currently under clinical development [9].”
BackgroundInfluentialJakubowska, A., Roux, C. W. L., & Viljoen, A. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1942 · Cited by 45
“Further GIP receptors are in the central nervous system including the hypothalamus, hippocampus, cerebral cortex, and olfactory bulb [20].”
BackgroundInfluential
Metadata
- Authors
- Tschöp, M., Nogueiras, R., & Ahrén, B.
- Affiliations
- Helmholtz Munich (DE)
- Venue
- Diabetologia
- Published
- 2023-05-20
- Volume
- 66
- Issue
- 10
- Pages
- 1796-1808
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC10474213
- OpenAlex
- W4377138246
- Cited by
- 92
- References
- 105
- Citations by year
- 2026: 23 · 2025: 23 · 2024: 33 · 2023: 12
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- Medicinska Fakulteten, Lunds Universitet (314314)
- Lund University
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, gastrointestinal hormones, type 2 diabetes, obesity, DPP-4 inhibitors, exendin-4, GIP/GLP-1 receptor agonist, insulin secretion, satiety, beta-cell function, energy expenditure, drug formulation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Body Weight, Diabetes Mellitus, Type 2, Glucagon, Glucose, Humans, Obesity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. https://app.cochat.ai/papers/10.1007/s00125-023-05929-0
- The paper
- Tschöp, M., Nogueiras, R., & Ahrén, B. (2023). Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. Diabetologia. https://doi.org/10.1007/s00125-023-05929-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.